Apple stores to stock chrome-plated glucose monitor from One Drop

The system features a predictive algorithm that forecasts glucose levels out to eight hours for Apple iOS users with type 2 diabetes, including those on oral medications or a basal insulin regimen. (Image: One Drop)

Apple, continuing its long march into healthcare, has begunstarted selling a fashionable, chrome-plated blood sugar monitor alongside its iPhones and Apple Watches in some of its U.S. retail stores. 

The glucose monitoring system, including a lancet, tester and strips, is developed by One Drop. It wirelessly syncs diabetes data with Apple’s devices and health apps, and had previously been available on the tech giant’s online storefront. 

Purchasers also receive one year of coaching via One Drop’s program, which includes digital tools for tracking medication, food intake and physical activity, and also offers test-strip subscription options. Apple had previously stocked Sanofi’s plug-in glucose meter for the iPhone, cleared in 2012. 

Survey

Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

"The healthcare industry is deeply invested in resisting progress, but consumerized, data-driven, digital health is becoming a reality," One Drop founder and CEO Jeff Dachis said in a statement

RELATED: Report: Study shows promise of Apple’s Health Records service

While not exactly a thrown sledgehammer, the system does feature a predictive algorithm that launched earlier this month, which forecasts glucose levels out to eight hours for Apple iOS users with type 2 diabetes, including those on oral medications or a basal insulin regimen.

RELATED: MannKind, One Drop to study Afrezza-app combo in Type 2 diabetes

One Drop says its machine learning-based predictions are powered by over 2.2 billion data points, collected from more than 1.2 million users. Alongside each forecast, users also receive advice on relevant behaviors for maintaining time-in-range.

Suggested Articles

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.

The FDA rejected the New Drug Application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.